S. 527 · 119th Congress
Prescription Pricing for the People Act of 2025
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Not yet voted on. This bill is still a proposal: it hasn't reached a floor vote, and its text can change in committee or on the floor before any vote.
R
GrassleySponsor13 cosponsors · 6 D, 7 R
D
Blumenthal
MC
D
Cantwell
SC
R
Capito
CC
D
Coons
MH
D
Hirono
JL
R
Lankford
RM
R
Marshall
TT
R
Tuberville
TT
R
Tillis
PW
D
Welch
JB
R
Boozman
MB
R
Blackburn
RW
D
Warnock10 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Prescription Pricing for the People Act of 20 25 This bill requires the Federal Trade Commission (FTC) to report about anticompetitive practices and other trends within the pharmaceutical supply chain that may impact the cost of prescription drugs.
What it does: CRS summary · Introduced in Senate · Feb 11, 2025
Prescription Pricing for the People Act of 2025
This bill requires the Federal Trade Commission (FTC) to report about anticompetitive practices and other trends within the pharmaceutical supply chain that may impact the cost of prescription drugs.
The report must address whether pharmacy benefit managers (PBMs) (1) reimburse pharmacies owned by the PBM at a higher price than other pharmacies, and (2) implement formulary designs to increase the market share of higher-cost prescription drugs or depress the market share of lower-cost prescription drugs.
The FTC also must provide recommendations to increase transparency in the supply chain, prevent anticompetitive practices, and ensure that consumers benefit from cost savings or efficiencies that result from mergers and consolidations.
Additionally, the FTC must report the number and nature of complaints the FTC receives relating to an allegation of anticompetitive conduct by a manufacturer of a sole-source drug.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Prescription Pricing for the People Act of 2025
Latest action (Apr 10, 2025): Placed on Senate Legislative Calendar under General Orders. Calendar No. 42.
Policy area: Commerce · Origin: Senate · Introduced: Feb 11, 2025
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.